FDA au­tho­rizes Pfiz­er's vac­cine boost­er for se­niors, those at high risk for se­vere Covid-19

The Biden ad­min­is­tra­tion’s goal of kick­ing off its boost­er shot dri­ve for the en­tire US pop­u­la­tion this week is not quite go­ing as planned.

First, Pfiz­er ap­plied for ap­proval of a sup­ple­men­tal ap­pli­ca­tion for the boost­er shots, but since last Fri­day’s ad­comm re­view­ing them, the plan has de­volved in­to an EUA, which the FDA is­sued late Wednes­day evening.

The pop­u­la­tion that is now el­i­gi­ble for the boost­er, six months af­ter re­ceiv­ing the first pair of Pfiz­er-BioN­Tech vac­cines, al­so nar­rowed from what Pfiz­er ap­plied for (every­one who’s el­i­gi­ble for the ini­tial Pfiz­er shots) to just those who are 65 or old­er, or at high-risk of a Covid in­fec­tion, in­clud­ing health care work­ers and oth­ers with oc­cu­pa­tion­al haz­ards.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER